Evidence map›Paper›PMID 35225390›Full record

ArticleIndoor air2022

Effectiveness of a novel semi-closed barrier device with a personalized exhaust in cough aerosol simulation according to particle counts and visualization of particles.

Ryohei Matsui, Hiroshi Sasano, Takafumi Azami, Hisako Yano, Hiromi Yoshikawa, Yota Yamagishi, Takahiro Goshima, Yuka Miyazaki, Kazunori Imai, Marechika Tsubouchi and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Indoor air, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ryohei MatsuiDepartment of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0001-8117-0252
Hiroshi SasanoDepartment of Advancing Acute Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Takafumi AzamiPathophysiology, Nagoya City University Graduate School of Nursing, Nagoya, Japan.
Hisako YanoInfection Control and Prevention Nursing, Nagoya City University Graduate School of Nursing, Nagoya, Japan.
Hiromi YoshikawaInfection Control and Prevention Nursing, Nagoya City University Graduate School of Nursing, Nagoya, Japan.
Yota YamagishiDepartment of Advancing Acute Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Takahiro GoshimaDepartment of Advancing Acute Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0002-9284-2584
Yuka MiyazakiDepartment of Advancing Acute Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Kazunori ImaiDepartment of Advancing Acute Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0002-1994-2466
Marechika TsubouchiDepartment of Advancing Acute Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yoichi MatsuoDepartment of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0001-9654-6080
Shuji TakiguchiDepartment of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0002-1339-354X
Tomonori HattoriDepartment of Advancing Acute Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0002-4503-2650
Nagoya City University · JP

Funding

Department of Advanced Acute Medicine, Nagoya City University
6 · The paper itself

Abstract

Oxygen therapy is an essential treatment for patients with coronavirus disease 2019, although there is a risk of aerosolization of additional viral droplets occurring during this treatment that poses a danger to healthcare professionals. High-flow oxygen through nasal cannula (HFNC) is a vital treatment bridging low-flow oxygen therapy with tracheal intubation. Although many barrier devices (including devices without negative pressure in the barrier) have been reported in the literature, few barrier devices are suitable for HFNC and aerosol infection control procedures during HFNC have not yet been established. Hence, we built a single cough simulator model to examine the effectiveness of three protective measures (a semi-closed barrier device, a personalized exhaust, and surgical masks) administered in isolation as well as in combination using particle counter measurements and laser sheet visualization. We found that the addition of a personalized exhaust to a semi-closed barrier device reduced aerosol leakage during HFNC without negative pressure. This novel combination may thus reduce aerosol exposure during oxygen therapy, enhance the protection of healthcare workers, and likely reduce nosocomial infection risk.

Indexed as

Air MicrobiologyAir Pollution, IndoorCOVID-19Respiratory Aerosols and DropletsCoughHumansSARS-CoV-2COVID-19high-flow nasal cannulanosocomial infection riskoxygen therapypersonalized exhaustsemi-closed barrier device

Identifiers

PMID35225390
PMCPMC9111386
OpenAlexW4213240148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.